SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors

Cancer patients are susceptible to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Different antitumor treatments have attracted wide attention in the context of coronavirus disease 2019 (COVID-19), especially immune checkpoint inhibitors (ICIs) that have revolutionized oncology change...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yang, Xu, Gaosi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313683/
https://www.ncbi.nlm.nih.gov/pubmed/37391394
http://dx.doi.org/10.1038/s41419-023-05922-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313683/
https://www.ncbi.nlm.nih.gov/pubmed/37391394
http://dx.doi.org/10.1038/s41419-023-05922-w

Ejemplares similares